Xdemvy is a prescription eye drop used to treat Demodex blepharitis, a common eyelid condition caused by tiny mites living in your eyelash follicles. It was approved by the FDA on July 24, 2023, making it the first medication specifically designed to target this type of blepharitis at its source.
What Demodex Blepharitis Is
Demodex blepharitis is an inflammatory condition of the eyelids driven by an overgrowth of Demodex mites, microscopic parasites that burrow into the base of eyelash follicles. These mites are extremely common and usually harmless in small numbers. When their population grows too large, they trigger chronic irritation, redness, itching, and a gritty sensation in the eyes.
The hallmark sign is something called collarettes: waxy, cylindrical deposits that form a collar around the base of your eyelashes. They’re made up of keratinized skin cells, undigested material, and mite debris (including eggs and egg casings). Collarettes sit right at the lash base rather than clinging to the lash shaft, which distinguishes them from the crusty flakes you see with bacterial forms of blepharitis. Studies have shown that 100% of eyes with collarettes test positive for Demodex mites, and a higher number of collarettes correlates with a more severe infestation. Your eye doctor can spot them during a slit-lamp exam by having you look downward to expose the upper lash line.
Before Xdemvy, treatment options were limited to lid scrubs, tea tree oil products, and other off-label remedies that addressed symptoms without directly killing the mites. None had been FDA-approved for the condition.
How Xdemvy Works
The active ingredient in Xdemvy is lotilaner, a compound originally developed for veterinary use against fleas and ticks. It belongs to a class of drugs called isoxazolines, which target a specific part of the mite’s nervous system. Lotilaner blocks a type of nerve channel in the mites that controls muscle function. Without these channels working properly, the mites go into spastic paralysis and die.
What makes this mechanism safe for humans is selectivity. Lotilaner targets mite nerve channels but does not affect the equivalent channels in mammals, even at concentrations roughly 1,100 times higher than the recommended dose. This means the drug is lethal to the mites living on your eyelids while posing minimal risk to your own tissues.
How the Treatment Works in Practice
The standard course is one drop in each eye, twice a day, spaced about 12 hours apart, for a total of six weeks. That’s the full treatment duration. Unlike many chronic eye medications that you take indefinitely, Xdemvy is a defined course with a clear endpoint.
The drops go directly onto the surface of your eye, not just the eyelid. From there, the medication reaches the mites at the base of your lashes. Most people incorporate the drops into a morning and bedtime routine to maintain the 12-hour spacing.
What Clinical Trials Showed
Xdemvy was evaluated in two pivotal clinical trials (called Saturn-1 and Saturn-2) that compared it against a vehicle control, essentially the same eye drop formulation without the active ingredient. In pooled results from both trials, the medication demonstrated statistically significant improvements in two key outcomes: clearance of collarettes from the eyelashes and reduction in mite counts.
These trials enrolled a broad range of adults with confirmed Demodex blepharitis. The results were strong enough for the FDA to grant approval based on the six-week treatment course alone, which is notable given that previous approaches to the condition typically required ongoing, indefinite management.
Side Effects to Expect
The most commonly reported side effect is stinging or pain at the site where the drop is applied, occurring in about 10% of patients in clinical trials. This is a brief sensation that happens right when the drop hits your eye and typically fades quickly.
Other side effects were much less common. About 1% of patients reported eye pain unrelated to the moment of instillation, and a similar percentage experienced temporary changes in visual clarity or mild itching at the application site. Dry eye, blurred vision, light sensitivity, and eye discharge were each reported in fewer than 1% of patients.
Overall, roughly 18% of patients on Xdemvy experienced at least one drug-related eye side effect during the six-week course. For context, about 15% of patients using the inactive vehicle drops also reported side effects, suggesting that some of these reactions come from the drop formulation itself rather than the active ingredient. No serious safety signals emerged from the trials, and the vast majority of side effects were mild and temporary.
Who Xdemvy Is For
Xdemvy is approved for adults with Demodex blepharitis. If you’ve been dealing with chronically red, irritated, itchy eyelids and over-the-counter lid scrubs or warm compresses haven’t solved the problem, Demodex mites may be the underlying cause. The presence of collarettes at the base of your lashes is the clearest indicator, and your eye care provider can check for them in a standard office visit.
People who have been cycling through treatments for “general blepharitis” or chronic dry eye without lasting improvement are particularly worth evaluating for Demodex. Because the condition was historically underdiagnosed and lacked a targeted treatment, many patients went years managing symptoms rather than eliminating the root cause. A six-week course of Xdemvy offers a fundamentally different approach: killing the mites directly rather than trying to manage the inflammation they produce.